Niemann-Pick Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Niemann-Pick disease (NPD) is a lysosomal storage disorder caused by acid sphingomyelinase deficiency (ASMD), which is characterized by the impairment of the enzyme responsible for the hydrolysis of sphingomyelin (SM) to ceramide and phosphocholine. The accumulation of SM and its precursor lipids within lysosomes, primarily in macrophages, leads to lipid-laden macrophages that deposit in various organs, including the liver, spleen, lungs, and brain. NPD leads to clinical symptoms such as hepatosplenomegaly, cytopenias, lung disease, and neurologic symptoms. NPD is classified into four subtypes: A, B, C, and E. The genetic basis of NPD is inherited in an autosomal recessive pattern, meaning that both copies of the gene must have mutations for the disease to manifest. NPD types A and B are caused by missense mutations in the sphingomyelin phosphodiesterase 1 (SMPD1) gene. NPD type C is caused by mutations in the NPC1 (located on chromosome 18) and NPC2 (located on chromosome 14) genes, which lead to abnormal or defective protein formation and impaired lipid transport out of cells, resulting in their accumulation within the cells. Differential diagnoses for NPD include other lysosomal storage disorders such as Gaucher, Tay-Sachs, and Metachromatic leukodystrophy. NPD is a progressive disorder; over time, complications can develop, such as fulminant hepatic failure, respiratory insufficiency, progressive neurodegeneration, severe thrombocytopenia, coronary artery and valvular heart disease, and deformation of bones.
- Niemann-Pick disease types A and B affect 1 in 250,000 individuals. NPD type C affects 1 in 150,000 individuals.
Thelansis’s “Niemann-Pick Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Niemann-Pick Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Niemann-Pick Disease across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Niemann-Pick Disease Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment